All In Biotech

Drug Trial Radar · NCT02366884

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments

Last checked: Nov 20, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Jul 26, 2011

Primary completion

Dec 31, 2022

Study completion Dec 31, 2023

Sponsor

Sponsor type
Industry
Collaborators
Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com
First posted
Feb 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The cell behavior that the investigators regard as "malignant," including: cell autonomy; invasion and digestion of surrounding normal tissues; migration and colonization of distant organs; ability to develop resistance to drugs, temperature, or radiation; and ability to kill the host, are not only characteristics of cancer cells, but of pathogenic and/or opportunistic unicellular organisms (bacteria, fungi and protozoa). Rudolf Virchow (1821-1902), the father of modern pathology, first pointed out the resemblance between the biological behavior of cancer cells and that of single-celled organisms when causing infections. He thought, incorrectly, that cancer cells were cells infected with bacteria and had acquired their pathogenic behavior from them. Others later postulated that the behavior of cancer cells was likely due to the re-expression of past traits and behaviors (atavism) derived from their past evolutionary experience as independent, single-celled organisms from which all cells in multicellular organisms originated. In other words, the behavior of pathogenic unicellular organisms, including: unlimited replicative potential; capacity for invasion, migration, and metastases; abilities to evade the host's immune system, to generate multi-drug resistance; and to kill a host, are what the investigators define as "cancer" when one of the investigators cells re-express these past ancestral traits. This reversion or de-evolution of a differentiated cell to its ancestral undifferentiated, unicellular form has been named "Atavistic Metamorphosis." This does not imply that cancer cells are bacteria, protozoa, or yeasts. It means that cancer cells express functions and/or behaviors similar to their ancestral parents, the unicellular organisms from which our cells originated. If this is true, a combination of drugs that are effective to eradicate certain unicellular organisms may work in cancer treatment. The principal objective of this study is to determine whether there is a benefit for patients with advanced, metastatic and terminal cancers to be treated with combinations of selected drugs conventionally used in medical practice to kill bacterial, fungal and protozoal cells.

Conditions

  • Neoplasms

Interventions

  • Anti-Bacterial AgentsDrug

    Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine

  • Anti-Fungal AgentsDrug

    Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole

  • Anti-Protozoal AgentsDrug

    Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical efficacy as measured by the number of participants with an objective clinical tumor regression responseTime frame: 6 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dr. Frank Arguello Cancer Clinic

    San José del Cabo, Baja California Sur, Mexico · Recruiting

  • Instituto de Ciencia y Medicina Genomica

    Torreón, Coahuila, Mexico · Enrolling by invitation

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.